VABYSMO® INJECTION 120 mg

Vabysmo (faricimab) 120 mg/mL solution for injection for intravitreal use.

VABYSMO is indicated for the treatment of patients with:

• Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
• Diabetic Macular Edema (DME)
• Macular Edema Following Retinal Vein Occlusion (RVO)

Vabysmo is used in adults to treat nAMD and DMO, which both affect the macula, the central part of the retina responsible for fine, central vision.

• Single-use vial for intravitreal use only.
• Vabysmo must be administered by a qualified physician experienced in intravitreal injections.
• Each vial should only be used for the treatment of a single eye.

Contraindications

• Ocular or periocular infection
• Active intraocular inflammation
• Hypersensitivity

After-care

• If a dose is delayed or missed, the patient should return to be assessed by physician at the next available visit and continue dosing depending on physician’s discretion.
• If visual and/or anatomic outcomes indicate that the patient is not benefiting from continued treatment, Vabysmo should be discontinued.
• No dose modifications of Vabysmo are recommended.